IRF2 and lung adenocarcinoma: Oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing interferon regulatory factor 2 expression [40], and may sensitize lung adenocarcinoma to GSK-J4-induced metabolic and oxidative stress [41]; moreover, KRAS-targeted anticancer strategies have been documented [42].